


PHARMACEUTICAL 2023

ASSEMBLY BIOSCIENCES INC. Rank 228 of 446









PHARMACEUTICAL 2023



ASSEMBLY BIOSCIENCES INC. Rank 228 of 446

The relative strengths and weaknesses of ASSEMBLY BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ASSEMBLY BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ASSEMBLY BIOSCIENCES INC. is the variable Net Income, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 38% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	96,967
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,296
Liabilities, Non-Current	2,834
Other Assets	4,084
Other Compr. Net Income	-384
Other Expenses	0
Other Liabilities	0
Other Net Income	1,022
Other Revenues	0
Property and Equipment	743
Research and Development	69,980
Selling, General and Administrative Expense	24,134

Output Variable	Value in 1000 USD
Assets	101,794
Liabilities	19,130
Expenses	94,114
Revenues	0
Stockholders Equity	82,664
Net Income	-93,092
Comprehensive Net Income	-93,284
Economic Capital Ratio	81%

